<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 21 patients suffering from <z:e sem="disease" ids="C0270786" disease_type="Disease or Syndrome" abbrv="">Binswanger's disease</z:e> (BD) and in 53 patients suffering from <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, we measured cerebrospinal fluid (CSF) concentrations of somatostatin-like immunoreactivity (SLI), high molecular weight form somatostatin (HMV-SST), somatostatin-25/28 (SST-25/28), somatostatin-14 (SST-14), Des-ala-somatostatin (Des-ala-SST), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) </plain></SENT>
<SENT sid="1" pm="."><plain>The patients were classified into three stages of <z:hpo ids='HP_0001268'>intellectual deterioration</z:hpo> according to the global deterioration scale (GDS) </plain></SENT>
<SENT sid="2" pm="."><plain>Levels of SLI were significantly decreased in BD in general and in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SDAT</z:e> patients with severe <z:hpo ids='HP_0000726'>dementia</z:hpo> (GDS 7), compared to a control group (BD overall 19.7 +/- 11.6 fmol/ml, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SDAT</z:e> 18.6 +/- 7.9 vs. 30.5 +/- 8.6 fmol/ml in controls, p &lt; 0.01 for both) </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SDAT</z:e> patients, SLI levels correlated with <z:hpo ids='HP_0000726'>dementia</z:hpo> scores (r = -0.65, p &lt; 0.05), but not in BD </plain></SENT>
<SENT sid="4" pm="."><plain>HVA levels were decreased significantly in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SDAT</z:e> and BD patients with severe <z:hpo ids='HP_0000726'>dementia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SDAT</z:e> 273.5 +/- 138.7, BD 224.3 +/- 69.9 vs. 364.9 +/- 103.8 nmol/ml, p &lt; 0.01 in controls, p &lt; 0.05 for both) </plain></SENT>
<SENT sid="5" pm="."><plain>In BD patients with light <z:hpo ids='HP_0000726'>dementia</z:hpo> (GDS 2-4), HVA levels were significantly elevated (p &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>In BD, HVA levels correlated with <z:hpo ids='HP_0000726'>dementia</z:hpo> (r = -0.59, p &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>5-HIAA was significantly elevated in BD patients with light <z:hpo ids='HP_0000726'>dementia</z:hpo> (p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Qualitative and quantitative changes in the molecular forms of SLI are compatible with a dysregulated posttranslational processing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SDAT</z:e> and BD </plain></SENT>
<SENT sid="9" pm="."><plain>We also observed significant correlations between SLI, 5-HIAA and HVA in BD indicating a neurochemical <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> and generalized process affecting several transmitter systems and functions </plain></SENT>
<SENT sid="10" pm="."><plain>In summary, our study shows that despite their quite different neuropathology, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SDAT</z:e> and BD do not differ fundamentally in their neurochemical profile </plain></SENT>
</text></document>